Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may predict dangerous transplant complication

NCT ID NCT01520623

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 70 patients who had a stem cell transplant for blood cancer. Researchers measured levels of complement proteins in the blood to see if they are linked to graft-versus-host disease, a common and serious side effect. The goal is to better understand how inflammation affects transplant success and find new targets for treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward new ways to prevent or treat graft-versus-host disease without weakening the anti-cancer effect of the transplant.
What could go wrong
This is an observational study, not a treatment trial. It only measures biological markers, so it cannot directly prove any new therapy works. The results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

70 people

The number who actually took part.

Start date

Apr 2010

Finished

Jul 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Allografted patients with myeloablative conditioning for an haematological malignancy * Age \> 18 years old and \< 65 years. * The patient must have access to social insurance according to local regulations. * Patient must give a written informed consent (personally signed and dated) before completing any study related procedure Exclusion Criteria: * Age \< 18 years old and \> 65 years * Patient with active infection HIV, HTLV1, Hepatite B ou C * Uncontrolled infection(s), (i.e. documented bacterial, parasitical, or fungal infection). * Patient with lupus * Patient with transaminases \> 5N, TP\<30% with Facteur V \< 30% before allogreffe * Creatinine clearance \< 50ml/min * Absence of any psychological condition potentially hampering signing informed consent * Patient refused to sign informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allografted with myeloablative conditioning are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

graft versus host disease hematopoietic and lymphoid cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allografted with myeloablative conditioning

Contacts and locations

Locations

  • Necker Hospital

    Paris, 75, France

  • Saint Antoine Hospital

    Paris, 75012, France

  • Saint Louis Hospital

    Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.